<DOC>
	<DOC>NCT00165698</DOC>
	<brief_summary>To determine the effect and safety of menatetrenone on treatment of postmenopausal osteoporosis comparing with alfacalcidol.</brief_summary>
	<brief_title>Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<mesh_term>Menatetrenone</mesh_term>
	<criteria>Inclusion criteria : Postmenopausal women with menopause duration more than 5 years and with age between 4575 years old (menopausal age ≥40), or if hysterectomy operated before natural menopause, the age of women between 6075 years old. Subject with BMD (L24 or neck of femur) being more than 2 Standard Deviation (SD) below the young female adult mean (According to the standard of each center) BMI between 18 kg/m230 kg/m2. The anatomic structure of lumbar spine must be available for Dualenergy Xray Absorptiometry (DEXA) examination, patient with serious scoliosis, bone trauma or sequela after orthopedics surgery, which makes BMD measurement difficult, should be excluded Subject who have given informed consent prior to participation in the trial and who undertake to comply with the protocol. Exclusion Criteria Subject with conditions that are considered to effect osteoporosis, such as clear definite diabetes mellitus, rheumatoid arthritis, rheumatoid arthritis, hyperparathyroidism or other bone metabolic diseases. Subjects who have received treatment with activetype vitamin D3 preparation, other vitamin D preparations (&gt;1000IU per day）, calcitonin, corticosteroid hormone, androgen, estrogen, other hormone, vitamin K preparation, in the 3 months prior to inanition of this study; Subjects who have received treatment with bisphosphonate preparation or Sodium Fluoride in the 1 year prior to inanition of this study; Subjects who have received treatment with Selective Estrogen Receptor Modulator (SERM) in the 6 months prior to inanition of this study Concurrent serious renal disease, hepatic disease, uncontrolled hypertension （≥150/100mmHg）, symptomatic ischemic heart disease, cerebral infarction or arteriosclerosis obliterans. Cancer history within 5 years. Subjects who take antacid containing aluminum in the preparation, warfarin or thrombolytic agents. Subject with any known abnormality in laboratory tests, which is deemed to be clinically significant by the investigator, which include: Serum alkaline phosphatace (ALP) &gt; upper normal limit 10% (calculated according to the range of normal values of each center); Glutamic Oxalacetic Transaminase (AST)/ Glutamic Pyruvic Transaminase (ALT) &gt; upper normal limit 50％(calculated according to the range of normal values of each center); Serum creatinine &gt;1.5mg/dL (133μmol/L); Bloodfasting sugar ≥ 7mmol/L (126mg/L) Inability of subject to return for scheduled visits or to comply with any other aspect of the protocol. Subject who, in the opinion of the investigator, are poor medical candidates or pose any other risk for therapy with an investigational drug.</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Postmenopausal</keyword>
	<keyword>osteoporosis</keyword>
</DOC>